U

pdated results were disclosed Wednesday night from a mid-stage clinical trial of Incyte’s epacadostat combined with Merck’s Keytruda to treat patients with metastatic melanoma.

The new data, culled from the study Incyte calls ECHO-202, look good, matching or exceeding investor expectations. Here’s a rundown:

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • As a Melanoma patient who has gone through 38 rounds of IL2 in 2010 and wondering when the Melanoma would become active again in my body, well I don’t have that on my mind anymore, I found out Thursday August 31 that it’s back, I was seeking some information, doing a little research for my options.
    I find it disgusting that you would withhold such vital information from the public and demand a ransom for it, I will be sure to tell everyone I know to avoid your website and cancel their subscriptions if they have one.

X